MFIC Announces Shipment of Microfluidizer® Processor Production System
News Oct 19, 2005
MFIC Corporation has announced that in the third quarter of 2005 it completed shipment of an M-7250-20 production level Microfluidizer system with the advanced functionality, controls and features incorporated to date in any system delivered by the Company.
The system was purchased by the Korean Institute of Industrial Technology ("KITECH").
KITECH states that as part of its mission it “not only focuses on strengthening the competitiveness of conventional technology but also on developing the next generation's strategic technology along with practical know-how.”
This high end Microfluidizer® processor system is in compliance with the FDA's current good manufacturing practice with automation (cGAMP) and includes features such as clean in place (CIP), steam in place (SIP) for sterilization, extensive real-time operating and monitoring controls and data acquisition and storage capabilities.
All controls and data are accessible through a stand-alone touch screen panel controller and interface.
MFIC acted as the integrator of the real-time process displays, program logic control (PLC) and instrumentation, data acquisition and automation systems (SCADA), and other components in the system.
Robert P. Bruno, President & COO, stated, “We believe that within KITECH there are and will continue to be significant scaleup opportunities for biotech processes using our Microfluidizer processor equipment.”
“Further, both the knowledge and skills acquired in design and construction of this advanced system has allowed us to secure other equipment orders and to quote on other prospective sales of our systems.”
Irwin Gruverman, CEO of MFIC Corporation stated, “The KITECH system will serve as a display of our capability to adapt our basic equipment design and function to the high level needs of a biopharma development plant.”
“We were pleased to have the opportunity to meet the challenges imposed by KITECH's leading edge specifications and to place our system in such a high visibility location.”
“KITECH's role as a contract research organization (CRO) should expose our equipment to many of the companies who work with KITECH and may need our equipment to scale up products and processes developed on the KITECH system.”
“In designing, building and testing this first of a kind system we incurred significant additional development costs and expenses that impacted profit on the sale of the system.”
“We believe that the demonstrational and developmental use of the KITECH system will provide significant future benefits to the Company."
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE